MyKids
Recruiting
Who can enter
Children and young adults with a newly diagnosed rare soft tissue sarcoma
Age: below 25 years old
Goal
Goal
The aim of this study is to learn more about the origin and behavior of rare soft tissue tumors in children and young adults. We want to do this by collecting data and doing research with a tumor tissue and blood. With this, we aim to improve the treatment of patients with soft tissue tumors in the future.
Background
Background
'Non-rhabdomyosarcoma soft tissue tumors’ is a collection of different types of rare tumors. Soft tissue tumors occur all over the body and arise in the soft tissues. The soft tissues are, for example, muscles, connective tissue, fatty tissue, or the wall of a blood vessel.
Very little is known about the origin of soft tissue tumors, especially this group with different types of rare soft tissue tumors. Within this study, we want to further investigate tumor tissue from children with these rare soft tissue tumors in the laboratory to learn more about their origin and behavior. By doing so, we hope to be able to diagnose patients better in the future and possibly develop better treatments.
Among other things, we investigate the tumors’ genetic material (DNA) and look for characteristics that predict how fast the tumor will grow. We also try to grow tumor cells outside the body in the laboratory so that we can use them for further research in the laboratory. We also collect data on the disease, treatment and treatment outcome of children from different hospitals in Europe.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
Last reviewed
March 23, 2026
Study details
- Study details
Official title
MYKIDS: Molecular Identification and Characterization of non-Rhabdomyosarcoma Soft Tissue Sarcoma in Kids, Adolescents and Young Adults: an EpSSG NRSTS studyCancer type
Non-rhabdomyosarcoma soft tissue sarcomasMaximum number of patients
250, of whom 25 are expected to participate in the NetherlandsStart date
May 17, 2024Status
OpenLocal principal investigator
Drs. N.K.A. van EijkelenburgSponsor
Princess Máxima Center for pediatric oncologyApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
Registry ISRCTN: ISRCTN12831761
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.